COVID-19InnovationNews

ERBA Mannheim Launches CE Marked ErbaLisa Covid-19 antibody ELISA kits

ERBA Mannheim, US Subsidiary of India’s largest IVD Company TRANSASIA Bio-Medicals

London: Erba Mannheim announced the development and imminent launch of its ErbaLisa COVID-19 ELISA kits for detection of IgG and IgM antibodies to SARS-CoV-2, in response to the global COVID-19 pandemic. The assays can be done either manually or with any open automated ELISA analyzer, such as the Erba Mannheim ELAN 30s. The ready-to-use ELISA kits will allow not only qualitative, but also semi-quantitative detection of the IgG and IgM antibodies.

SARS-CoV-2 viral antigens stimulate the body’s immune system to produce antibodies that can be detected with IgM and IgG antibody tests. IgM is produced first and is detectable during early onset of the disease. IgG is produced later and is maintained for long-term immunity.

Petros Sarantos, Global Product Manager for Immunoassay, said, “Our IgM test could be used to identify people recently infected by the virus, including those who may not have displayed symptoms. The IgG test will provide an accurate measure of how many people have been infected and may have developed immunity. Once identified, immune individuals could safely return to work and help relieve stressed healthcare systems or other frontline functions. Such people could also donate their blood to potentially save other patients with severe COVID-19.”

Nikhil Vazirani, MD of Erba Mannheim, said “We are very proud to be contributing towards the fight against COVID-19. Having a better understanding about the immunity of COVID-19 will help society move back towards normality.”

Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals said that the test will be available in India soon. “Transasia launched COVID Antibody ELISA Test having 98% Accuracy approved by CE & US FDA. Will shortly be Made in India at AMTZ,” he said in a tweet.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
IndiaMedToday
Close
Close